Every material Form 8-K Alaunos Therapeutics, Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alaunos Therapeutics said Nasdaq confirmed it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, closing the matter and canceling the November 10, 2026 hearing before the Nasdaq Hearings Panel. Its common stock will continue to be listed and traded on The Nasdaq Capital Market, removing the near-term delisting risk for shareholders.
Nasdaq notified the company on April 9, 2026 that it was not in compliance with the $2,500,000 stockholders' equity requirement.
The company said a private placement completed on October 14, 2026 led it to believe it had regained compliance.
On October 22, 2026, Nasdaq's Office of General Counsel confirmed compliance and closed the matter.
The hearing scheduled for November 10, 2026 was cancelled.
Alaunos Therapeutics said it believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement, following the October 14, 2026 closing of a financing with aggregate gross proceeds of approximately $350.0 million. Nasdaq has not yet confirmed the company's determination, and a Nasdaq Hearings Panel hearing remains scheduled for November 10, 2026. The company's status could still be challenged if it does not evidence compliance when it files its 2026 annual report.
Nasdaq's April 9, 2026 deficiency letter cited stockholders' equity of $2,153,000 in the 2025 Form 10-K, below the $2,500,000 minimum.
The financing closed October 14, 2026, with approximately $350.0 million in gross proceeds before placement agent fees and other expenses.
A Fairmount Fund II waiver covers 6,268 Series C Preferred shares, valued at approximately $9.0 million, that would otherwise carry a cash settlement right.
The Panel hearing is set for November 10, 2026; the company expects it to be cancelled once Nasdaq confirms compliance, and Nasdaq will keep monitoring the requirement.
Alaunos Therapeutics completed its merger with privately held Velaris Therapeutics on October 13, 2026, making Velaris a wholly owned subsidiary. A concurrent $350 million private placement is expected to close on October 14, 2026, and the filing says Velaris holders and the investors will receive large amounts of convertible preferred stock, which can convert into common shares and would dilute existing stockholders once converted.
Velaris holders received 105,286 Series B and 33,054 Series C non-voting convertible preferred shares, each convertible into 1,000 common shares, subject to conditions.
Private placement covers 687,789 common shares at $1.4357 per share and 243,063 Series C preferred shares at $1,435.70 per share, for an aggregate purchase price of approximately $350 million.
Stockholder meeting proposals include conversion approval, an authorized share increase, a name change to Velaris Therapeutics, a reverse stock split and a new equity plan; three directors are to resign upon conversion approval.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alaunos Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →